Department of Endocrinology and Metabolism, Center for Diabetes and Metabolism Research, Laboratory of Diabetes and Islet Transplantation Research, West China Hospital of Sichuan University, Chengdu, China.
Front Endocrinol (Lausanne). 2023 Oct 11;14:1234918. doi: 10.3389/fendo.2023.1234918. eCollection 2023.
To probe the appropriate iodine nutritional status for patients with Graves'disease (GD) hyperthyroidism and on antithyroid drugs (ATD) or after drugwithdrawal.
Studies were retrieved from three databases (Embase, Medline, and Cochrane Library) and were screened and evaluated using predefined criteria. The risk of bias of each trial was assessed using a tool from Cochrane. The iodine nutritional status of the subjects was redefined according to the World Health Organization (WHO) criteria and classified as insufficient/adequate/above requirements/excessive iodine intake.
Two randomized controlled trials (RCTs) and 3 observational studies were selected from the 376 retrieved papers, which had different degrees of risk of bias in study design. The heterogeneity among them prevented us from further synthesizing effect indicators and subsequent statistical analyses. Two RCTs with high quality showed that insufficient or above requirements iodine intake was detrimental for ATD-treated GD patients; adequate iodine intake was associated with a lower risk of recurrence and better efficacy in controlling thyrotoxicosis. It could be speculated from three low-quality observational studies that excessive iodine intake may be associated with higher (or similar) recurrence rates and lower remission rates compared to above requirements iodine intake in these patients, but none of them could answer the question of the effect of insufficient or adequate iodine intake on this issue.
Although the available evidence is suboptimal, this systematic review tentatively suggests that in adult patients with GD hyperthyroidism receiving ATDs and according to WHO criteria for iodine nutritional status, adequate iodine intake is associated with a lower recurrence rate, a higher remission rate and a better efficacy to control thyrotoxicosis than insufficient, above requirement, or excessive iodine intake. Future RCTs with large samples are expected to elucidate the actual impact of different iodine nutritional statuses on the recurrence rate of hyperthyroidism and the efficacy of ATD to control thyrotoxicosis in these patients.
identifier CRD42022359451.
探讨格雷夫斯病(GD)甲状腺功能亢进症患者及抗甲状腺药物(ATD)治疗或停药后碘营养状态的适宜范围。
从 Embase、Medline 和 Cochrane Library 三个数据库中检索相关研究,并采用预先设定的标准进行筛选和评估。采用 Cochrane 工具评估每项试验的偏倚风险。根据世界卫生组织(WHO)标准重新定义研究对象的碘营养状况,分为碘摄入不足/充足/过量。
从 376 篇检索文献中选择了 2 项随机对照试验(RCT)和 3 项观察性研究,这些研究在研究设计上存在不同程度的偏倚风险。由于它们之间存在异质性,我们无法进一步综合效应指标和进行后续的统计分析。两项高质量 RCT 表明,碘摄入不足或过量对 ATD 治疗的 GD 患者不利;碘摄入充足与复发风险降低和控制甲状腺毒症的疗效更好相关。从 3 项低质量观察性研究中可以推测,与碘摄入过量相比,过量碘摄入可能与这些患者的复发率较高(或相似)和缓解率较低相关,但没有一项研究能够回答碘摄入不足或充足对这一问题的影响。
尽管现有证据不理想,但本系统评价初步表明,在接受 ATD 治疗的 GD 甲状腺功能亢进症成年患者中,根据 WHO 碘营养状况标准,碘摄入充足与复发率降低、缓解率提高和控制甲状腺毒症的疗效更好相关,而碘摄入不足、过量或碘摄入过量与碘摄入不足、过量或碘摄入过量相关。预计未来会有更多大样本 RCT 阐明不同碘营养状态对这些患者甲状腺功能亢进症复发率和 ATD 控制甲状腺毒症疗效的实际影响。
标识符 CRD42022359451。